Oct 14, 2019
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
Oct 09, 2019
Immutep Announces Data Presentations at Upcoming Industry Conferences
Immutep Receives A$2.5 Million R&D Tax Incentive from French Government
Sep 25, 2019
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
Sep 22, 2019
Immutep to Receive £4M Milestone Payment from GSK
Sep 16, 2019
Immutep Announces Japanese Patent Grant for LAG525 Antibody
Aug 21, 2019
Immutep Granted European Patent for Eftilagimod Alpha in Cancer
Aug 06, 2019
Immutep Completes A$6M Entitlement Offer
Jul 26, 2019
Operational Update
Jul 09, 2019
Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer
Jun 25, 2019
Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
Jun 24, 2019
Immutep to Host Key Opinion Leader Call
